1 Dasari A, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol, 2017;3(10):1335–1342.
2 Kim, J Y, Hong SM, Ro JY, Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11–16.
3 Lloyd R, et al. WHO Classification of Tumours of Endocrine Organs. Fourth Edition. WHO Classification of Tumours, Volume 10, IARC; 2017.
4 Basturk O, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683–90.
5 Sorbye H, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol, 2013;24(1):152–60.
6 Falconi M, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153–71.
7 Jensen, RT, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology, 2012;95(2):98–119.
8 Strinović M, et al. Duodenal neuroendocrine tumors (d-NETs): challenges in diagnosis and treatment. Vol. 15. 2016;168–173.
9 Begum N, Maasberg S, Pape U, Epidemiologische Daten des Deutschen NET-Registers. TumorDiagn u Ther. 2017;38(01):30–34.
10 Hayes, AR, Davar J, Caplin ME, Carcinoid Heart Disease: A Review. Endocrinol Metab Clin North Am, 2018;47(3):671–682.
11 Kocha W, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol, 2010;17(3):49–64.
12 Pavel M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511–9.
13 Fottner C, Ferrata M, Weber MM, Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose? Rev Endocr Metab Disord. 2017;18(4):393–410.
14 Ramage, JK, et al. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103(2):139–43.
15 Valli, PV, Mertens J, Bauerfeind P, Safe and successful resection of difficult GI lesions using a novel single-step full-thickness resection device (FTRD((R))). Surg Endosc. 2018;32(1):289–299.
16 Choi, JH, et al. Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors. Endoscopy, 2018.
17 Jacobs, MA, et al. Neuroendocrine tumors: beyond the abdomen. J Comput Assist Tomogr. 2014;38(6):898–914.
18 Bushnell DL, Baum RP, Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am, 2011;40(1):153–62, ix.
19 Chiti A, et al., Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med. 1998;25(10):1396–403.
20 Dromain C, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23(1):70–8.
21 Rufini V, ML Calcagni, Baum RP, Imaging of neuroendocrine tumors. Semin Nucl Med, 2006;36(3):228–47.
22 Albanus DR, et al. Clinical value of (6)(8)Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET). Eur J Radiol. 2015;84(10):1866–72.
23 Fani M, Nicolas GP, Wild D, Somatostatin Receptor Antagonists for Imaging and Therapy. J Nucl Med, 2017. 58 Suppl 2:S61–6.
24 Nicolas GP, et al. Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. J Nucl Med. 2018;59(6):915–21.
25 Niederle B, et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology, 2016;103(2):125–38.
26 Pape UF, et al. ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology, 2016;103(2):144–52.
27 Delle Fave G, et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology, 2016;103(2):119–24.
28 Nell S, et al. Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group. Ann Surg, 2018;267(6):1155–1160.
29 Lewis A, et al. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival with or without Liver Treatment. Ann Surg; 2018.
30 Frilling A, et al, Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8–21.
31 Mazzaferro V, et al. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. Am J Transplant. 2016;16(10):2892–2902.
32 ENETS, Current Guidelines. ENETS Consensus Guidelines for the Diagnosis and Treatment of Neuroendocrine Tumors.
https://www.enets.org/current_guidelines.html; 2016.
33 Rinke A, et al., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.
34 Caplin ME, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.
35 Pavel, M., et al., Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018;25(3):309–322.
36 Strosberg J, et al., Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125–135.
37 Faivre S, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol, 2017. 28(2):339–343.
38 Mohan H, et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol, 2015. 26(7): p. 935–942.e1.
39 Öberg U, et al. Perceptions of Persons With Type 2 Diabetes Treated in Swedish Primary Health Care: Qualitative Study on Using eHealth Services for Self-Management Support. JMIR Mental Health. 2018;3(1):e7.
40 Kennedy A, et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015;17(1):29–37.
41 Strosberg JR, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268–75.
42 Kim J, Kim JH, Lee JY, Chun J, Im JP, Kim JS. Clinical outcomes of endoscopic mucosal resection for rectal neuroendocrine tumor. BMC Gastroenterol. 2018 Jun 5;18(1):77.